



**Company** Epistem Plc  
**TIDM** EHP.L (AIM)  
**Headline** Epistem announces installation of UKs first Bruker Xtreme Imaging system  
**Released** 7th April 2014 (UK:7.00am)

### **Epistem announces installation of UKs first Bruker Xtreme Imaging system**

Marketwire: Epistem Holdings Plc (LSE: EHP), Manchester, UK, the biotechnology and personalized medicine company, today announced the successful installation of the Bruker Xtreme Imaging System within its contract research services division. This is the first such machine in the UK and will enable Epistem to expand both the range and throughput of its imaging services, particularly in the field of oncology. The Bruker Xtreme provides high sensitivity luminescence, fluorescence, radio-isotopic and radiographic (X-ray) imaging. Combined with Epistem's specialized pre-clinical knowledge this increases the range of assays the company can provide to its clients as well as their ability to identify new targets for cancer therapy.

"We are excited to have installed the UKs first machine. This new platform combines highly sensitive capabilities in a unified system, and provides us with a means to track tumour cells, visualise inflammation, and provide high throughput pharmacodynamic studies." said Dr. Catherine Booth, Co-Founder and Managing Director of the Contract Services Business. "Epistem's contract research service is committed to providing high quality, reliable and innovative pre-clinical models and services."

*Bruker commented "The successful installation of the Xtreme system at Epistem marks our first UK site. The Xtreme is a highly sensitive imaging system with the added advantages of modularity and flexibility. It's unique design will provide major benefits to Epistem's pre-clinical drug development services."*

For further details please contact:

#### **Epistem Plc**

Matthew Walls: Chief Executive Officer  
John Rylands: Finance Director

++44 161 606 7258

#### **Notes for editors**

Epistem is a biotechnology and personalised medicine company commercialising its expertise in stem cells in the areas of epithelial (oncology, gastrointestinal and dermatological) and infectious diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics (Genedrive®) alongside contract research services for drug development companies. The Group's core expertise is focused around the regulation of adult stem cells located in epithelial tissue including the gastrointestinal tract, skin, hair follicles, breast and prostate and utilizing novel, proprietary next generation molecular biology for use in personalised medicine. [www.epistem.co.uk](http://www.epistem.co.uk)